Africa’s Place in Precision Medicine: Implications for Global Health Equity and Health Systems

Abstract

Precision medicine, which is based on the idea of tailoring health care for individual genetic, environmental, and lifestyle factors, is rapidly revolutionizing biomedical research and clinical practice across the world. Despite the progress across the world, Africa only has a limited representation in precision medicine research and implementation. This view looks at where Africa stands today in the precision medicine sphere and identifies gaps in genomic data, infrastructure, workforce capacity, and policy frameworks. It examines the implications of these gaps for health equity globally the potential dangers of growing health disparities if African populations are not included in research and innovation. Furthermore, it outlines the strategies to enhance Africa’s involvement in precision medicine, such as capacity building, regional partnerships, investment in bioinformatics, and research policies to ensure inclusivity. Strengthening Africa’s role in precision medicine is crucial not only for improving health at the local level but also for ensuring equitable health outcomes across the globe.

Introduction: Where Is Africa In the Precision Medicine Conversation?

Precision medicine, the individualization of health care according to genetic, environmental, and lifestyle factors, has quickly transformed biomedical research and clinical practice worldwide. From pharmacogenomic drug optimization, gene-based diagnostic tools, and cancer genomics, high-income regions have leveraged genomic data and advanced analytics to transform the paradigms of disease prevention and treatment. Yet in this transformative era, Africa, a continent with the greatest human genetic diversity and rapidly increasing health burden, is conspicuously underrepresented in global precision medicine developments.

This perspective article considers the role Africa plays in precision medicine from a global perspective and then focuses inward, where progress, challenges, and opportunities unique to the continent are assessed. The article is a synthesis of knowledge across regions to point to underexplored gaps and propose directions for research, infrastructure, and policy to position Africa at the heart of the precision medicine conversation.

Precision Medicine in a Global Context

Evolution and world adoption

Precision medicine was born out of the convergence of the large-scale genomic projects and better computational capacity. In North America and Europe, national projects like the All of Us Research Program (the United States) or the UK Biobank (the United Kingdom) have created enormous data files that connect genetic profiles to health outcomes, allowing for powerful population-specific insights. Simultaneously, countries such as China and Japan have made genomic research part of the wider health care policy and invested heavily in sequencing technologies, bioinformatics, and molecular diagnostics.

Intergovernmental initiatives in precision medicine focus not only on genomic sequencing but also on longitudinal phenotypic data collection, multiomic integration, and artificial intelligence (AI) analytics to produce actionable precision health insights. These efforts on the global scale have helped in the development of polygenic risk scores, targeted therapy, and pharmacogenomic guidelines that can be used to inform clinical decision-making and minimize adverse drug reactions.

However, even within these high-income environments, challenges remain regarding data privacy, ethical management of genetic information, and equitable access, underscoring that precision medicine is as much a social and policy challenge as it is a scientific one.

The Paradox of Genetic Diversity and Underrepresentation

Africa’s deep genetic diversity based on its status as the cradle of humanity is one of the most significant, yet largely untapped, resources for precision medicine research. Studies show that existing genomic data worldwide currently overrepresents European and Asian ancestry populations, while African ancestry populations make up less than a small fraction of the world’s genomic data. This disparity has very real consequences: Genetic variants that affect disease susceptibility, drug metabolism, and clinical response in African populations are less well-characterized than in other populations. Without various genomic representations, predictive models and therapeutic recommendations may not generalize well to African contexts. ¹

This underrepresentation contributes to a blind spot being seen throughout the world: Polygenic risk scores developed mostly from European ancestry datasets often perform poorly on datasets collected in African populations because of differences in linkage disequilibrium structures and allele frequencies. Consequently, precision medicine tools developed in other parts of the world may have limited utility or, worse, give inaccurate guidance when applied in an African clinical setting.

New Initiatives in Africa

Despite this gap in history, African researchers and institutions are working to reduce these inequities. Regional efforts like the Personalized Medicine in North Africa consortium are focused on strengthening regional infrastructure, workforce expertise, and creating genomic data of relevance to North African populations. ²

In southern Africa, institutions such as the Centre for Proteomic and Genomic Research ³ in South Africa are making progress in genomic sequencing capabilities that will support the research in precision medicine locally. ⁴ Such efforts include collaborations incorporating proteomics, bioinformatics, and genome sequencing to offer context-specific information about the mechanism of disease and response to drugs.

Countries throughout Africa are also starting to incorporate genomic approaches into national health plans, with initiatives in Ghana, Ethiopia, Malawi, Mozambique, Zambia, and Nigeria connecting genomics with public health functions such as pathogen surveillance and outbreak response. ⁵

Important Barriers to Precision Medicine in Africa

Infrastructure and Capacity Deficits

A fundamental hurdle to the adoption of precision medicine in Africa is a lack of genomic infrastructure from genomic sequencing facilities to biobanks to high-performance computing capabilities for extensive data analysis and computation. Where they exist, genomic technologies tend to be concentrated in a few research centers, limiting the accessibility of those technologies for broader clinical or public health applications. The development of national initiatives like South Africa’s 110,000 human genome program is evidence of strategic commitment to fill this gap by developing a sovereign genomic reference database, but such a program is still rare on the continent. ⁶

The lack of trained geneticists and bioinformaticians and clinician scientists also limits capacity. While professional bodies such as the African Society for Bioinformatics and Computational Biology promote training and networking in the region, the process of building and retaining talent is a long-term task.

Data Ecosystems and Clinical Integration

Precision medicine requires powerful data ecosystems connecting genetic data to longitudinal data on clinical and lifestyle factors. In many African settings, electronic health records are fragmented or absent, and systems for incorporating genomic data with clinical outcomes are underdeveloped. This raises fundamental challenges of conducting research and translating to clinical practice.

Additionally, clinical trials involving African populations are disproportionately low; only a small percentage of trials conducted globally occur in Africa, reducing the opportunities to validate precision medicine applications in a number of genetic contexts. ⁷

African Countries Pushing Precision Medicine Forward: Leaders, Lessons, and Gaps

A few countries in Africa are taking the lead in the fields of precision medicine and integration of genomics and can provide models for how strategic investment, policy alignment, and collaboration can catalyze progress.

South Africa and Egypt are the most noticeable. In South Africa, the government has identified genomics and precision medicine as national priorities, and there is extensive infrastructure and research to support this. National programs, including the Southern African Human Genome Program and initiatives under the Strategic Health Innovation Partnership, and investment from the Department of Science and Innovation have resulted in advances in genomic research and bioinformatics capacity and increased local sequencing and data analysis capability. The South African 110,000 Human Genome Program, in collaboration with international tech companies, is working toward the creation of a sovereign reference database that will enhance clinical research and support decision-making in precision health in various contexts. These efforts are also related to workforce training and inclusion in participation, including historically disadvantaged groups.

Egypt has also initiated national genomic-based initiatives, such as the Egyptian Genome Program, which spans wide segments of the population and is in collaboration with European research frameworks for precision medicine. Northern African countries such as Algeria, Morocco, and Tunisia are also making progress on initiatives to introduce genomics into health systems such as cancer biobanks and diagnostics.

In sub-Saharan Africa, multinational initiatives like Human Heredity and Health in Africa (H3Africa) in more than 30 African countries offer an invaluable pan-continental framework for developing genomic research capacity, bioinformatics networks, and biorepositories. H3Africa has already built up tens of thousands of genomic samples and supports research infrastructure and training that goes directly into precision medicine.

Other countries, Ghana, Ethiopia, Malawi, Mozambique, Zambia, and Nigeria, have built genomics into public health frameworks and sequencing initiatives that support pathogen surveillance, genetic epidemiology, and early work in disease-specific precision approaches. ⁵

Opportunities for the Advancement of African Precision Medicine

Exploiting African Genetic Variety

Africa’s genetic diversity is not just a local asset; it has a global scientific significance. Deeply diverse populations provide opportunities to identify novel genetic variants associated with disease resistance, drug response, and susceptibility. By promoting large-scale, inclusive biobanking and genomic research efforts, African research organizations can contribute uniquely valuable biobanking and genomic data sets that will boost precision medicine for all populations.

Strengthening Collaborative Research Ecosystems

Precision medicine does not evolve in a vacuum: It grows in networks of collaboration that involve interdisciplinary expertise, infrastructure, and funding. In many high-income settings, there is some collaboration among academic institutions, biotechnology companies, and public agencies to speed discovery and translation. Africa is starting to build such ecosystems, but the scale and integration of collaboration are still lagging behind the global standards.

One example is cross-institutional genomic research partnerships that can bring together African data generation efforts with global analytical expertise. Regional consortia and efforts are emerging to help fill the gap in history. These collaborative networks want to reverse obsolete paradigms where African scientists were simply used as sample collectors for studies designed from elsewhere on the continent. Instead, current efforts emphasize African-lead research agendas, which prioritize biomedical goals to be coupled with local health needs.

However, such alliances frequently rely on external funding and collaborations with multinational biotech companies or foreign universities, all of which raise key questions of ownership of data and agenda setting and equitable benefit sharing. For collaboration to be truly sustainable, African institutions must play the leadership role in defining research questions, protocols, and governance frameworks that reflect the priorities of the continent, as opposed to transactional relationships with global partners.

Ultimately, a matured ecosystem will bring together clinicians, geneticists, data scientists, and policymakers from across Africa with their counterparts in other continents, bridging the disciplines of disease biology and implementation science and ensuring that precision medicine is both a source of novel knowledge and a tool for the population it is intended to benefit.

Implementation Science and Clinical Translation

Translating information from the genome into real-world clinical practice is the cauldron of precision medicine. In many developed economies, precision health tools have become a part of routine care, from cancer gene panels to direct therapeutic choices to pharmacogenomic tests to avoid adverse drug reactions. Yet in the majority of health settings across Africa, implementation science is at an early stage.

One of the main reasons is that a lot of data to develop guidelines for precision medicine worldwide has come from populations with predominantly European or Asian ancestry. Tools like polygenic risk scores or drug response algorithms trained on these datasets may not work well on African populations where the genetic variation may vary dramatically, thus needing indigenously generated genomic evidence.

Several African centers are starting to translate regional research into practice by building community-anchored precision health programs based on disease burdens in the region. These programs combine genomic data with clinical outcomes to make better diagnoses and treatment decisions. For example, pharmacogenomic initiatives are discovering unique African variants in key drug metabolism genes—variants that affect response to common drugs in conditions ranging from cancer to hypertension. Harnessing such insights could have a major impact on improving the effectiveness of therapeutics and minimizing adverse events in a range of African patient populations.

Policy Implications for WHO and National Health Systems

At the global level, the World Health Organization (WHO) stands in a pivotal convening and normative place that offers directions on how precision medicine may be operationalized in the context of public health practice in low and middle-income countries. Rather than addressing the genomic and digital innovations as expensive, stand-alone ventures, the WHO can ensure that precision medicine becomes part of the health systems in Africa by providing normative guidance on what we may call “precision public health.” Such guidance would help to clarify how genomic and digital tools are to be integrated into existing primary health care and universal health coverage frameworks, with the emphasis on integration rather than separation. Technical recommendations should include minimal standards for ethical genomic data governance, equitable access to precision diagnostics, and the responsible application of AI risk-stratification tools in population health programs. By embracing this framework, countries will avoid fragmented and donor-driven pilots and link emerging technologies to their national health priorities and systemic capacities.

At the national level, Ministries of Health should transform precision medicine from theory to practice by integrating genomics-informed approaches into existing public health operations, instead of creating stand-alone programs. Practical places to start could include using pharmacogenomic data to shape essential medicines policies, integrating pathogen and human genomic data into disease surveillance systems, and phasing in precision diagnostics at referral-level care for high-burden diseases like oncology, cardiovascular disease, and infectious disease. Crucially, such initiatives must be guided by national implementation plans that define priority use cases, workforce-training needs, data-governance mechanisms, and pathways for equitable access so that precision medicine strengthens health systems, not exacerbates inequities.

Positioning precision medicine within WHO’s existing normative frameworks is an essential prerequisite for it to be ethically responsibly adopted in African health systems. The longstanding commitments to universal health coverage, primary health care fortification, and the judicious use of digital health technologies by WHO can offer a policy scaffold for precision public health. When viewed through these lenses, precision medicine no longer becomes an abstract, high-technology aspiration but becomes a pragmatic tool for making health services more efficient, safe, and equitable. Aligning genomics and data-driven innovations with WHO guidance on health systems strengthening issues, essential diagnostics, and ethical governance of emerging technologies ensures that precision strategies become part of population health objectives rather than remaining in research contexts.

Policy Framework and Sustainable Financing

Policy and financing structures have a large influence on the pace and equity of the adoption of precision medicine. In high-income countries, national strategies usually involve genome strategies, reimbursement for genetic testing, and the incorporation of precision health metrics in national systems. Africa, however, is still in the early stages of policy framing for precision medicine.

Some countries have started to express national genomic strategies or have genomics components in more general health policies, indicating political awareness of the potential of precision medicine. These frameworks focus on capacity building and ethical governance. Yet policy translation into operational standards, including licensure for genetic testing, reimbursement for precision diagnostics, and regulatory oversight for data governance, remains patchy. Without robust policy and regulatory frameworks that establish standards for genetic testing, ensure equitable access to diagnostics, and govern data use, the practice of precision medicine runs the risk of advancing only where private investment or external collaborations are available, thereby deepening rather than reducing health inequities.

Financing is another challenge in parallel. Comprehensive genomic platforms and data infrastructures need sustained investments not only in equipment and laboratory facilities but also in human capital and digital systems. Historically, African health financing has focused on responding to immediate public health emergencies and communicable diseases. While these remain urgent needs, balancing investment and long-term precision medicine strategies will require innovative financing models that include a mix of public funding, strategic partnerships, philanthropic support, and more targeted industry engagement. Sustainable financing, not only scientific discoveries but also equitable access to precision health services across socioeconomic strata, is imperative.

Community Engagement and Ethical Stewardship

Precision medicine brings up complex ethical questions about data ownership, consent, and the control of genetic data. These challenges are particularly acute in African settings, in which legacies of exploitation and uneven research partnerships still exist with an urgent need to ensure that the generation and use of genomic data are consistent with principles of equity, community engagement, and cultural relevance.

In many African societies, collective values such as shared responsibility and mutual benefit, anchored in communal philosophies like Ubuntu, provide alternative paradigms to data governance that differ from Western individualistic models. Emerging conversations attempt to include these African ethical frameworks, stressing communal values and shared responsibility in genomics research governance (Bukini, 2025). ⁸ Grounding genomic research in these values means co-learning with communities about consent, transparent use of data, and benefit sharing in reciprocity. Governance models that include African epistemologies can help to bridge trust gaps and ensure that the benefits of precision medicine are mutual and community-centered, not extractive.

Data sovereignty is another critical issue. Genomic datasets are immensely valuable scientifically and commercially, so clear rules regarding ownership, access, and benefit sharing are essential. Without strong legal and ethical frameworks, it is possible that African genomic data obtained as part of research collaborations could be controlled by entities outside of the continent with little benefit flowing back to local populations. Ethical governance must, therefore, balance the need for individual privacy with the need for strengthening collective interests in health innovation.

Equally important is public involvement and health literacy in terms of precision medicine. Too often, assumptions about genomic research do not consider the need for broad community understanding of genetics, risk, and the implications of personalized health information. Investment in education from primary care clinicians to community advocates builds a social foundation on which precision medicine will have to stand.

Conclusion: Changing the Conversation to Africa-Led Precision Medicine

Precision medicine offers a transformative potential to rethink the way health care is practiced not only in terms of molecular understanding but also in a fundamental redefinition of who creates knowledge and who benefits from it. Africa, with its unmatched genetic diversity and rapidly developing science ecosystem, is in a unique position. The underrepresentation of the continent in genomic research has long been a global blind spot, a lost opportunity both in terms of African health equity and the advancement of human health science more broadly.

Yet current shifts in the emergence of African-led genomic programs, growing collaborative networks, and integrative efforts to build infrastructure and governance point toward a future in which Africa is not only a participant in the precision medicine conversation but also a leader in shaping its trajectory. Realizing that the future needs strategic investments in capacity building, equitable partnerships, ethical governance, and community engagement.

Crucially, the global scientific community will need to understand that the promise of precision medicine to individualize care and improve the health of populations will be an impossible mission to achieve without Africa’s voice, data, and leadership at the table. Only in promoting an environment in which African priorities drive research agendas and implementation strategies can precision medicine achieve its potential to address both global and local health challenges with the nuance, justice, and scientific excellence that it holds.